RhumbLine Advisers
KZIA

RhumbLine Advisers’s Kazia Therapeutics KZIA Stock Holding History

RhumbLine Advisers’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Sell
1,402
-163
-10% -$1.14K ﹤0.01% 3801
2025
Q4 		$10.8K Buy
1,565
+974
+165% +$8.3K ﹤0.01% 3845
2025
Q3 		$4.32K Hold
591
– – ﹤0.01% 3925
2025
Q2 		$3.66K Buy
591
+209
+55% +$976 ﹤0.01% 3945
2025
Q1 		$1.49K Sell
382
-174
-31% -$1.03K ﹤0.01% 4004
2024
Q4 		$4.91K Hold
556
– – ﹤0.01% 3960
2024
Q3 		$12K Buy
556
+204
+58% +$4.07K ﹤0.01% 3867
2024
Q2 		$4.01K Buy
352
+109
+45% +$1.62K ﹤0.01% 4116
2024
Q1 		$3.83K Buy
243
+49
+25% +$734 ﹤0.01% 4016
2023
Q4 		$4.36K Buy
194
+43
+28% +$1.26K ﹤0.01% 4006
2023
Q3 		$7.55K Hold
151
– – ﹤0.01% 3915
2023
Q2 		$8.61K Buy
+151
New +$9.52K ﹤0.01% 3983

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RhumbLine Advisers's KZIA Position: Q1 2026 in Review

RhumbLine Advisers reduced its Kazia Therapeutics (KZIA) stake by 10% in Q1 2026, selling an estimated $1.14K and leaving 1,402 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3801.

RhumbLine Advisers first reported a position in KZIA in Q2 2023 and has held it in 12 quarters since. The position peaked at $12K in Q3 2024. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • RhumbLine Advisers held 1,402 shares of Kazia Therapeutics worth $10.4K as of Q1 2026.
  • RhumbLine Advisers sold 163 Kazia Therapeutics shares in Q1 2026, an estimated $1.14K.
  • Kazia Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3801 holding.
  • RhumbLine Advisers first reported a position in Kazia Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Kazia Therapeutics position peaked at $12K in Q3 2024.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.